CATT follow-up: Visual acuity in 50% of patients still 20/40 or better at 5 years

Regardless of treatment drug, either bevacizumab or ranibizumab, visual acuity gains seen in the first 2 years of the CATT study were not maintained at 5 years, according to data reported at the American Society of Retina Specialists meeting in San Francisco.However, visual acuity was 20/40 or better in half of patients at 5 years, Daniel F. Martin, MD, chairman of the Cleveland Clinic Cole Eye Institute and the study chair for CATT, said.